Mobile app version of munafa.org
Login or Join
 Learn then Earn
stockMarketNEWS

 story : : FDA panel to meet Thursday to discuss full approval of Paxlovid #FinanceUSA #StockMarketNEWS A Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should

@stockMarketNEWS 9 Days ago

Posted in: #FinanceUSA #StockMarketNEWS

: FDA panel to meet Thursday to discuss full approval of Paxlovid #FinanceUSA #StockMarketNEWS
A Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should grant full approval to Paxlovid, the antiviral pill developed by Pfizer PFE to treat high-risk COVID infections. The FDA in late 2021 authorized the drug, which generated .9 billion in sales in 2022. However, as the intensity of the pandemic has waned, Paxlovid is expected to bring in .3 billion in sales this year. In briefing documents released in advance of the meeting, the regulator said it did not “identify a clear association between” Paxlovid and rebound infections, which occur when someone tests negative and starts to feel better before a reoccurrence of COVID symptoms and positive test results.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme